SG11201806581TA - Combination products for the treatment of rsv - Google Patents
Combination products for the treatment of rsvInfo
- Publication number
- SG11201806581TA SG11201806581TA SG11201806581TA SG11201806581TA SG11201806581TA SG 11201806581T A SG11201806581T A SG 11201806581TA SG 11201806581T A SG11201806581T A SG 11201806581TA SG 11201806581T A SG11201806581T A SG 11201806581TA SG 11201806581T A SG11201806581T A SG 11201806581TA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- international
- rsv
- beerse
- imidazo
- Prior art date
Links
- 229940126062 Compound A Drugs 0.000 abstract 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- -1 MBX-300 Chemical compound 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- QZSZPSDRJPPZDZ-OAQYLSRUSA-N (9bs)-9b-(4-chlorophenyl)-1-(pyridine-3-carbonyl)-2,3-dihydroimidazo[5,6]pyrrolo[1,2-a]pyridin-5-one Chemical compound C1=CC(Cl)=CC=C1[C@]1(C2=CN=CC=C2C2=O)N2CCN1C(=O)C1=CC=CN=C1 QZSZPSDRJPPZDZ-OAQYLSRUSA-N 0.000 abstract 1
- ZJSVBILSBHWRTN-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-c]pyridin-2-one Chemical compound C1=NC=C2NC(=O)NC2=C1 ZJSVBILSBHWRTN-UHFFFAOYSA-N 0.000 abstract 1
- KSHJXDWYTZJUEI-UHFFFAOYSA-N 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound N=1C2=CC=CC=C2N(CCCCO)C=1CN(C1=O)C2=CN=CC=C2N1C1CC1 KSHJXDWYTZJUEI-UHFFFAOYSA-N 0.000 abstract 1
- BLUJRJMLDHEMRX-UHFFFAOYSA-N 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1N=Cc1ccc(O)c(c1)C(c1ccc(O)cc1)c1cc(C=Nn2nnnc2C)ccc1O BLUJRJMLDHEMRX-UHFFFAOYSA-N 0.000 abstract 1
- DKORMNNYNRPTBJ-UHFFFAOYSA-N 2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(CCCO)C(NCC=2C=C3N(CC=4C(=CC=C(C)N=4)O)C(NCCCN4CCOCC4)=NC3=CC=2)=C1 DKORMNNYNRPTBJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- CKCODSNUWCBRIS-UHFFFAOYSA-N 5-[[4,6-bis[3-[bis(3-amino-3-oxo-propyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(3-amino-3-oxo-propyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfo-phenyl]benzenesulfonic acid Chemical compound NC(=O)CCN(CCC(N)=O)S(=O)(=O)C1=CC=CC(NC=2N=C(NC=3C=C(C(C=4C(=CC(NC=5N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CCC(N)=O)CCC(N)=O)N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CCC(N)=O)CCC(N)=O)N=5)=CC=4)S(O)(=O)=O)=CC=3)S(O)(=O)=O)N=C(NC=3C=C(C=CC=3)S(=O)(=O)N(CCC(N)=O)CCC(N)=O)N=2)=C1 CKCODSNUWCBRIS-UHFFFAOYSA-N 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- GOFXWTVKPWJNGD-UWJYYQICSA-N n-[2-[(2s)-2-[5-[(3s)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide Chemical compound CC1=CN2N=C([C@H]3N(CCCC3)C(=O)C=3C(=CC=C(Cl)C=3)NS(C)(=O)=O)C=C2N=C1N1CC[C@H](N)C1 GOFXWTVKPWJNGD-UWJYYQICSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229960000402 palivizumab Drugs 0.000 abstract 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 1
- ZETYKEPFFRMVBX-UHFFFAOYSA-N rfi 641 Chemical compound NC(=O)CN(CC(N)=O)S(=O)(=O)C1=CC=CC(NC=2N=C(NC=3C=C(C(C=4C(=CC(NC=5N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=5)=CC=4)S(O)(=O)=O)=CC=3)S(O)(=O)=O)N=C(NC=3C=C(C=CC=3)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=2)=C1 ZETYKEPFFRMVBX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011111111101111011001111101111011111 International Bureau 0.. .... .. ..... ..or::,„, (10) International Publication Number (43) International Publication Date WO 2017/134133 Al 10 August 2017(10.08.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/437 (2006.01) A61K 31/53 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/7056 (2006.01) A61K 31/5377 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61P 31/12 (2006.01) A61K 31/55 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 39/395 (2006.01) A61K 31/5513 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/41 (2006.01) A61K 31/70 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 31/4184 (2006.01) A61K 31/519 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 31/52 (2006.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, PCT/EP2017/052201 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 2 February 2017 (02.02.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 16154035.6 3 February 2016 (03.02.2016) EP DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: JANSSEN SCIENCES IRELAND UC SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, [IE/IE]; Eastgate Village, Eastgate Little Island, Co Cork GW, KM, ML, MR, NE, SN, TD, TG). (E). — Declarations under Rule 4.17: (72) Inventors: YSEBAERT, Nina; c/o Janssen Pharmaceutica — as to applicant's entitlement to apply for and be granted a _ NV, Turnhoutseweg 30, 2340 Beerse (BE). 4.17(u)) . GOEYVAERTS, Nele Isa E.; Janssen Pharmaceutica patent (Rule c/o NV, Turnhoutseweg 30, 2340 Beerse ROYMANS, Published: (BE). Dirk Andre E.; c/o Janssen Pharmaceutica NV, Turnhout- - with international search report (Art. 21(3)) seweg 30, 2340 Beerse (BE). KOUL, Anil; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). — before the expiration of the time limit for amending the = claims and to be republished in the event of receipt of — _ (74) Agent: VERBERCKMOES, Filip; J&J Patent Law De- 48.2(h)) amendments (Rule partment, Turnhoutseweg 30, 2340 Beerse (BE). M = = = = = = = (54) Title: COMBINATION PRODUCTS FOR THE TREATMENT OF RSV ,-1 (57) : The present invention is directed to the combination of the RSV inhibiting Compound A, 3-({5-chloro-1 43- i.e. ..! (methylsulfonyl)propy1]-1 11-indo1-2-yllmethyl)-1 -(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A- M en 60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1 43-(methylsulf- onyl)propy11- 1 11-benzimidazol-2-y1 1 methyl)-1 cyclopropyl- 1,3-dihydro -2H-imidazo [4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl - 71' sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methy1]-1 -cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylpheny1)-6-(4-(5- en methyl-2-(7-oxa-2-azaspiro [3 .5]nonan-2 yOnicotinamido)benzoy1)-5,6-dihydro-4H-benzo [b]thieno [2,3- d]azepine-2-carboxamide, 1-1 ---- and 4-amino-8434[2-(3,4-dimethoxyphenypethyl]aminotropyl]-6,6-dimethyl-2-(4-methyl 3-nitropheny1)-3H-imidazo[4,5- IN h]isoquinoline-7,9(6H,8H)-dione, for treating or ameliorating RSV infection. The invention further relates to the combination C product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Com - N pound B, the use of the combination of Compound A and one or more of Compound B - or the pharmaceutical product comprising O CompoundA and one or more Compound B - for the treatment of RSV infection, and a method of treating or ameliorating RSV in- fection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16154035 | 2016-02-03 | ||
| PCT/EP2017/052201 WO2017134133A1 (en) | 2016-02-03 | 2017-02-02 | Combination products for the treatment of rsv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806581TA true SG11201806581TA (en) | 2018-09-27 |
Family
ID=55304886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806581TA SG11201806581TA (en) | 2016-02-03 | 2017-02-02 | Combination products for the treatment of rsv |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10363253B2 (en) |
| EP (2) | EP3411028B1 (en) |
| JP (1) | JP7065030B2 (en) |
| KR (1) | KR20180108598A (en) |
| CN (2) | CN112245429A (en) |
| AU (2) | AU2017214246B2 (en) |
| BR (1) | BR112018014958A2 (en) |
| CA (1) | CA3006488A1 (en) |
| CL (3) | CL2018001808A1 (en) |
| EA (3) | EA037206B1 (en) |
| ES (1) | ES2877808T3 (en) |
| IL (2) | IL259669B (en) |
| MX (2) | MX2018009422A (en) |
| MY (1) | MY197217A (en) |
| PH (2) | PH12018501649A1 (en) |
| SG (1) | SG11201806581TA (en) |
| UA (1) | UA124099C2 (en) |
| WO (1) | WO2017134133A1 (en) |
| ZA (1) | ZA201805205B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189863B2 (en) | 2014-10-10 | 2019-01-29 | Pulmocide Limited | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives |
| US10160772B2 (en) | 2014-12-18 | 2018-12-25 | Pulmocide Limited | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives |
| WO2017175000A1 (en) | 2016-04-08 | 2017-10-12 | Pulmocide Limited | Compounds |
| TW201936193A (en) | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | Treatment of RSV with combination product |
| MX2022005257A (en) * | 2019-10-30 | 2022-06-09 | Janssen Sciences Ireland Unlimited Co | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H- INDOL-2 YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H</i >-IMIDAZO[4,5-C]PYRIDIN-2-ONE. |
| CN114014856B (en) * | 2021-11-26 | 2023-12-22 | 嘉兴安谛康生物科技有限公司 | Imidazopyridine derivatives as respiratory syncytial virus antiviral agents |
| CN116077494A (en) * | 2023-01-11 | 2023-05-09 | 黑龙江中医药大学 | Pharmaceutical composition for treating respiratory syncytial virus and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI515187B (en) * | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | Indoles as respiratory syncytial virus antiviral agents |
| PL2988780T3 (en) * | 2013-04-25 | 2019-06-28 | Janssen Vaccines & Prevention B.V. | Stabilized soluble prefusion rsv f polypeptides |
| JP6485817B2 (en) * | 2013-08-21 | 2019-03-20 | ヤンセン バイオファーマ インク． | Antiviral compound |
| US10189863B2 (en) * | 2014-10-10 | 2019-01-29 | Pulmocide Limited | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives |
-
2017
- 2017-02-02 EA EA201891655A patent/EA037206B1/en unknown
- 2017-02-02 ES ES17702125T patent/ES2877808T3/en active Active
- 2017-02-02 US US16/075,103 patent/US10363253B2/en active Active
- 2017-02-02 EA EA202092251A patent/EA202092251A1/en unknown
- 2017-02-02 MX MX2018009422A patent/MX2018009422A/en unknown
- 2017-02-02 KR KR1020187020776A patent/KR20180108598A/en not_active Application Discontinuation
- 2017-02-02 CN CN202010988991.4A patent/CN112245429A/en active Pending
- 2017-02-02 JP JP2018540796A patent/JP7065030B2/en active Active
- 2017-02-02 AU AU2017214246A patent/AU2017214246B2/en active Active
- 2017-02-02 SG SG11201806581TA patent/SG11201806581TA/en unknown
- 2017-02-02 WO PCT/EP2017/052201 patent/WO2017134133A1/en active Application Filing
- 2017-02-02 MX MX2020012592A patent/MX2020012592A/en unknown
- 2017-02-02 CN CN201780009640.0A patent/CN108601774B/en active Active
- 2017-02-02 EP EP17702125.0A patent/EP3411028B1/en active Active
- 2017-02-02 EA EA202092250A patent/EA202092250A1/en unknown
- 2017-02-02 UA UAA201809060A patent/UA124099C2/en unknown
- 2017-02-02 EP EP21170919.1A patent/EP3892273A3/en active Pending
- 2017-02-02 MY MYPI2018001388A patent/MY197217A/en unknown
- 2017-02-02 CA CA3006488A patent/CA3006488A1/en active Pending
- 2017-02-02 BR BR112018014958A patent/BR112018014958A2/en not_active Application Discontinuation
-
2018
- 2018-05-29 IL IL259669A patent/IL259669B/en active IP Right Grant
- 2018-06-29 CL CL2018001808A patent/CL2018001808A1/en unknown
- 2018-08-02 PH PH12018501649A patent/PH12018501649A1/en unknown
- 2018-08-02 ZA ZA2018/05205A patent/ZA201805205B/en unknown
-
2019
- 2019-05-29 CL CL2019001455A patent/CL2019001455A1/en unknown
- 2019-05-29 CL CL2019001454A patent/CL2019001454A1/en unknown
-
2020
- 2020-09-10 IL IL277281A patent/IL277281B/en active IP Right Grant
- 2020-09-29 PH PH12020551598A patent/PH12020551598A1/en unknown
-
2022
- 2022-03-25 AU AU2022202070A patent/AU2022202070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806581TA (en) | Combination products for the treatment of rsv | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors |